Sienna+MR Long-term Uptake
Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Aargau
-
Baden, Aargau, Switzerland
- Kantonsspital Baden
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
inclusion:
- participation in previous study
- informed consent
- no contraindications for MRI scan
exclusion:
- contraindications for MRI scan
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Native 1,5 Tesla breast MRI group
From all patients a 1,5 Tesla MRI of the breast will be obtained
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
I) Analysis if the supraparamegnetic Tracer is still detectable
Time Frame: 04/2017
|
Analysis by two expert radiologists
|
04/2017
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analysis to which degree of impairment of Imaging is detected
Time Frame: 04/2017
|
Description as "no impairment", impairment, but Interpretation of Images possible", "impairment, Image Interpretation impossible"
|
04/2017
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016-00808
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
NCT05452213RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer
-
NCT07607366RecruitingBreast Cancer - Female
-
NCT07529496Not yet recruiting
-
NCT07331506RecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating Ductal Carcinoma
-
NCT07242118Recruiting
-
NCT07357207Enrolling by invitationFemale Breast Cancer Patients
-
NCT07214883RecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer Awareness
-
NCT07482384Not yet recruitingBreast Cancer | Breast Carcinoma | ER Positive Breast Cancer | Breast Cancer - Female | PR-Positive Breast Cancer
-
NCT07298252CompletedBreast Neoplasms | Breast Cancer Screening | Breast Cancer Detection | Breast Cancer - Female
-
NCT06952270Not yet recruitingBreast Cancer | Breast Cancer Survivor | Breast Cancer Patients | Breast Cancer - Female
Clinical Trials on Native 1,5 Tesla breast MRI
-
NCT03200457CompletedIron Hepatic Overload | Fat Hepatic Overload
-
NCT02751606UnknownBreast Neoplasms | Rectal Neoplasms
-
NCT04941430TerminatedMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain
-
NCT04318028CompletedStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Non-Metastatic Prostate Carcinoma
-
NCT05895656Withdrawn
-
NCT02576743Completed
-
NCT01945853WithdrawnAmyotrophic Lateral Sclerosis (ALS)
-
NCT04539574CompletedGlioma | Metastatic Malignant Solid Neoplasm | Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous System
-
NCT02731521CompletedMalignant Gliomas | Astrocytomas | Oligodendrogliomas